Daiichi Sankyo Company Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Daiichi Sankyo Company wird ein jährliches Gewinn- und Umsatzwachstum von 19.5% bzw. 12.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.6% betragen.

Wichtige Informationen

19.5%

Wachstumsrate der Gewinne

18.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	12.4%
Zukünftige Eigenkapitalrendite	19.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:DSNK.Y - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	2,431,823	356,206	275,765	454,737	15
3/31/2026	2,081,665	263,260	182,242	374,555	16
3/31/2025	1,828,484	221,268	284,889	375,584	12
9/30/2024	1,758,071	250,400	417,387	587,088	N/A
6/30/2024	1,687,028	229,101	407,158	535,454	N/A
3/31/2024	1,601,688	200,731	476,467	599,258	N/A
12/31/2023	1,503,471	186,052	509,483	601,669	N/A
9/30/2023	1,397,025	147,885	-79,581	4,025	N/A
6/30/2023	1,348,996	147,350	15,149	89,040	N/A
3/31/2023	1,278,478	109,188	47,148	114,514	N/A
12/31/2022	1,182,201	59,354	52,831	120,225	N/A
9/30/2022	1,122,724	62,816	85,820	153,864	N/A
6/30/2022	1,061,140	50,603	74,484	148,554	N/A
3/31/2022	1,044,892	66,972	62,544	139,226	N/A
12/31/2021	1,034,692	94,470	91,294	161,092	N/A
9/30/2021	1,012,313	86,756	52,721	111,874	N/A
6/30/2021	989,638	79,321	58,547	106,238	N/A
3/31/2021	962,516	75,958	128,114	192,207	N/A
12/31/2020	963,552	70,599	123,806	188,054	N/A
9/30/2020	982,388	116,315	132,076	206,119	N/A
6/30/2020	969,501	117,584	96,878	174,904	N/A
3/31/2020	981,793	129,074	144,036	196,601	N/A
12/31/2019	983,669	148,891	137,641	212,138	N/A
9/30/2019	962,440	113,821	120,648	187,666	N/A
6/30/2019	953,219	112,805	113,638	181,424	N/A
3/31/2019	929,717	93,409	25,420	92,033	N/A
12/31/2018	922,228	66,479	38,321	85,284	N/A
9/30/2018	937,648	70,018	49,447	97,072	N/A
6/30/2018	946,829	55,081	N/A	96,957	N/A
3/31/2018	960,195	60,282	N/A	108,439	N/A
12/31/2017	961,766	37,887	N/A	99,826	N/A
9/30/2017	966,509	38,758	N/A	83,608	N/A
6/30/2017	953,255	52,017	N/A	102,946	N/A
3/31/2017	955,124	53,466	N/A	136,234	N/A
12/31/2016	962,296	59,736	N/A	161,540	N/A
9/30/2016	965,681	60,572	N/A	184,039	N/A
6/30/2016	989,001	77,951	N/A	181,513	N/A
3/31/2016	986,446	82,282	N/A	174,281	N/A
12/31/2015	839,759	55,256	N/A	139,346	N/A
9/30/2015	872,744	67,132	N/A	146,907	N/A
6/30/2015	903,340	61,708	N/A	151,239	N/A
3/31/2015	919,372	46,762	N/A	142,776	N/A
12/31/2014	1,149,342	88,276	N/A	N/A	N/A
9/30/2014	1,127,233	80,437	N/A	119,883	N/A
6/30/2014	1,120,177	69,910	N/A	N/A	N/A
3/31/2014	1,118,241	60,943	N/A	37,304	N/A
12/31/2013	1,059,287	90,021	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DSNK.YDas prognostizierte Gewinnwachstum (19.5% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: DSNK.YDie Erträge des Unternehmens (19.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: DSNK.YDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DSNK.YDie Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: DSNK.YDie Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DSNK.YDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.6%).

Daiichi Sankyo Company Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Recent updates

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024

IHH Healthcare Berhad Provides Update on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken